PT-141 Research
Melanocortin Receptor Research Peptide
melanocortin pathways
Weight and Wellness
Stress and Anxiety
Libido, Hormones and Menopause
Educational information only. Investigational uses may lack FDA approval. Not medical advice or a treatment plan.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist studied for its activity at MC3 and MC4 receptors in the central nervous system. A pharmaceutical version (Vyleesi) received FDA approval for hypoactive sexual desire disorder in premenopausal women. Research covers several signaling areas:
Research areas
Melanocortin Receptor Signaling
Research focuses on PT-141's activity at MC3 and MC4 receptors and its downstream effects on dopamine and norepinephrine signaling pathways.
Sexual Function Pathway Research
Studies examine its role in libido-related neural pathways, sexual arousal signaling, and desire-related CNS activity in both men and women.
Mood & Motivation Signaling
Researchers investigate its influence on dopaminergic pathways involved in mood, motivation, and reward-system signaling research.
Energy & CNS Activation Research
Studies explore its role in central nervous system activation signaling, alertness pathways, and energy-related neurological research.
A pharmaceutical version (Vyleesi/bremelanotide) is FDA-approved for HSDD in premenopausal women. PT-141 as a research peptide is investigational. Not medical advice.
Have questions about PT-141?
Request a free consultation to ask questions and learn more about this research area.
Request a free consultation